Phase 3 trial results show roflumilast cream 0.05% to be a safe and effective treatment for children with atopic dermatitis.

Dermatologists wax poetic about changing your skin care routine with the seasons. As we head into the warmer spring months, ...

A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic eczema achieved a “super-response,” by week 16, according to a presenter at the American Academy of ...

The following is a summary of “Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.